TOP TIERMARKET NEWSWIRE

News & sentiment

ROCHE HLDG LTD ADR (RHHBY) — News & AI sentiment

ROCHE HLDG LTD ADR (RHHBY) news roundup. 10 stories in the past week, 31 over 30 days. Average 30-day sentiment is 64.4/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

10

avg sentiment 61.6/100

30d stories

31

avg sentiment 64.4/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

RHHBY news in the last 24 hours, 7 days, 30 days and 90 days

How much RHHBY coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	RHHBY stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	10	61.6/100	RHHBY headlines →
Last 30 days	31	64.4/100	RHHBY headlines →
Last 90 days	73	65/100	RHHBY headlines →

Latest stories on RHHBY

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

StockTitan74 · bullishproduct/pr

5d ago

Deutsche Bank upgrades Roche on bullish physician feedback for cancer drug

Investing.com Markets64 · neutralanalyst

5d ago

Roche upgraded to Buy from Hold at Deutsche Bank

The Fly63 · neutralanalyst

5d ago

Roche Q3 results beat on revenue, though pharma sales a slight miss

Seeking Alpha58 · neutralearnings

6d ago

Roche, In A Buy Zone, Matches Sales Views On Its Diagnostics Beat

Investors.com58 · neutralearnings

6d ago

Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales

Investors.com52 · neutralearnings

6d ago

Roche CEO Signals New Wave of Drugs to Fuel Growth Next Year, Beyond — Update

Morningstar63 · neutralearnings

6d ago

Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units

Morningstar63 · neutralearnings

6d ago

Roche third quarter sales slightly beat expectations with growth across divisions

Reuters58 · neutralearnings

6d ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

GlobeNewswire63 · neutralearnings

6d ago

Roche says experimental MS pill cuts relapses by 55% in late-stage trials

Reuters74 · bullishproduct/pr

Oct 21

Roche intends to make comeback with oncology pill treatment, Bloomberg says

The Fly63 · neutralproduct/pr

Oct 21

Roche upgraded to Outperform from Underperform at Oddo BHF

The Fly64 · neutralanalyst

Oct 20

Roche and Hansoh sign cancer drug deal worth over $15 billion - qz.com

Quartz74 · bullishm&a

Oct 19

Roche Partners With China’s Hansoh in Deal That Could Top $15 Billion

WSJ Business64 · neutralm&a

Oct 19

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

StockTitan58 · neutralproduct/pr

Oct 19

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

GlobeNewswire58 · neutralproduct/pr

Oct 19

Roche: FDA Approves Enspryng

MarketWatch74 · bullishproduct/pr

Oct 16

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

StockTitan74 · bullishproduct/pr

Oct 16

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

GlobeNewswire78 · bullishproduct/pr

Oct 16

Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics

Reuters64 · neutralm&a

Oct 13

Roche’s Genentech Secures FDA Approval for Tecentriq in Stage III Colon Cancer

InvestorsHub84 · bullishproduct/pr

Oct 9

FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application

Stocktwits News56 · neutralgeneral

Oct 5

RHHBY, Roche Holding ADR | IBD Stock Checkup

Investors.com50 · neutralgeneral

Oct 4

Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

StockTitan50 · neutralgeneral

Oct 1

Open RHHBY in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →